Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $12.91B | $190.67M | $0.94 |
| 2024 | $11.27B | $-18.06M | $-0.09 |
| 2023 | $8.83B | $-154.60M | $-0.90 |
| 2022 | $7.72B | $-53.91M | $-0.31 |
| 2021 | $6.70B | $49.80M | $0.29 |
Social Signal Score
Earnings
Thu, Oct 29(in 2 months)
Consensus estimate $0.46 per share
Typical surprise +15.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Jul 31$0.45 vs $0.40beat
- Fri, May 1$0.39 vs $0.29beat
- Fri, Feb 27$0.33 vs $0.34miss
- Fri, Oct 31$0.30 vs $0.26beat
- Fri, Aug 1$0.22 vs $0.19beat
- Fri, May 2$0.19 vs $0.08beat
Estimates and results for BTSG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from BTSG's reported EPS growth of 34.2% a year over 4 years. Historical EPS growth of 34% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $3.49
- Implied price
- $139.79
- Return from $61.71
- 17.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $69.50 — today's price is already 11.2% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 28 | 34 | 40 | 46 | 52 |
|---|---|---|---|---|---|
| 20.0% | 1.2% | 5.2% | 8.7% | 11.8% | 14.6% |
| 25.0% | 5.4% | 9.6% | 13.2% | 16.4% | 19.3% |
| 30.0% | 9.7% | 14.0% | 17.8% | 21.1% | 24.1% |
| 35.0% | 13.9% | 18.4% | 22.3% | 25.8% | 28.9% |
| 40.0% | 18.1% | 22.8% | 26.8% | 30.4% | 33.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (2)
- Newszacks.com·3d ago·Neutral
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now BTSG's specialty, infusion and home health momentum support growth, while IRA pressure and customer exits may weigh on near-term margins.
View source ↗ - Newsseekingalpha.com·5d ago·Neutral
BrightSpring Health Services: A Great Business, But I'm Waiting For A Better Entry BrightSpring Health Services (BTSG) has delivered 22% revenue CAGR over five years, with strong segment growth and a compelling integrated care platform. BTSG's Onco360 specialty pharmacy and high-margin Provider Solutions drive recurring revenue, benefiting from secular demand and insurer preference for integrated services. Valuation suggests limited upside despite strong growth prospects.
View source ↗